GenEdit Polymer Nanoparticles Rushed by Sarepta GenEdit Polymer Nanoparticles Rushed by Sarepta By Daniel Scott on February 3, 2022 In the near future, Sarepta Therapeutics will pay GenEdit up to $57 million for access to the Eli Lilly-backed biotech’s non-viral gene editing delivery platform.…